Medical oncologist Heather Parsons, MD, MPH, witnessed how cancer affects the entire family when her younger sister was ...

Severe gastrointestinal inflammation could occur in 2 percent to 3 percent of patients who receive Carvykti, the FDA has informed patients and doctors.

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) ...

After undergoing treatment for Stage 2 Hodgkins lymphoma, Hardee Bhavsar is on a journey to cross items off her bucket list ...

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's ...

Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and highly aggressive form of mature T-cell leukemia NEW YORK, (GLOBE NEWSWIRE) -- ...

Researchers from the Schweitzer Biotech Company in Taiwan have created a serum which shows promising results for patients ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation ...

BeOne Medicines said the Food and Drug Administration has granted Breakthrough Therapy Designation for sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.